- Conformational study of an artificial metal-dependent regulation site for use in designer proteins
-
This report describes the dimerisation of glutathione, and by extension, other cysteine-containing peptides or protein fragments, with a 5, 5'-disubstituted-2, 2'-bipyridine or 6, 6''-disubstituted-2, 2':6',2''-terpyridine unit. The resulting bipy-GS2 and terpy-GS 2 were investigated as potential metal ion dependent switches in aqueous solution, and were found to predominantly adopt the transoid conformation at physiological pH. Metal complexation with CuII and ZnII at this pH has been studied by UV/Vis, CD, NMR and ion-mobility mass spectrometry. ZnII titrations are consistent with the formation of a 1:1 ZnII:terpy-GS2 complex at pH 7.4, but bipy-GS2 was shown to form both 1:1 and 1:2 complexes with the former being predominant under dilute micromolar conditions. Formation constants for the resulting 1:1 complexes were determined to be log KM 6.86 (bipy-GS2) and 6.22 (terpy-GS2), consistent with a higher affinity for the unconstrained bipyridine, compared to the strained terpyridine. CuII coordination involves the initial formation of 1:1 complexes, followed by 1.5Cu:1bipy-GS2 and 2Cu:1terpy-GS2 complexes at micromolar concentrations. Binding constants for formation of the 1:1 complexes (log KM 12.5 (bipy-GS2); 8.04 and 7.14 (terpy-GS2)) indicate a higher affinity for CuII than ZnII. Finally, ion-mobility MS studies detected the free ligands in their protonated form, and were consistent with the formation of two different Cu adducts with different conformations in the gas-phase. We illustrate that the bipyridine and terpyridine dimerisation units can behave like conformational switches in response to Cu/Zn complexation, and propose that in future these can be employed in synthetic biology with larger peptide or protein fragments, to control large scale folding and related biological function. Copyright
- Oheix, Emmanuel,Spencer, Neil,Gethings, Lee A.,Peacock, Anna F. A.
-
-
Read Online
- Synthesis and physico-chemical properties of homoleptic copper(I) complexes with asymmetric ligands as a dssc dye
-
To develop low-cost and efficient dye-sensitized solar cells (DSSCs), we designed and prepared three homoleptic Cu(I) complexes with asymmetric ligands, M1, M2, and Y3, which have the advantages of heteroleptic-type complexes and compensate for their synthetic challenges. The three copper(I) complexes were characterized by elemental analysis, UV-vis absorption spectroscopy, and electrochemical measurements. Their absorption spectra and orbital energies were evaluated and are discussed in the context of TD-DFT calculations. The complexes have high VOC values (0.48, 0.60, and 0.66 V for M1, M2, and Y3, respectively) which are similar to previously reported copper(I) dyes with symmetric ligands, although their energy conversion efficiencies are relatively low (0.17, 0.64, and 2.66%, respectively).
- Hatano, Mayuka,Inomata, Tomohiko,Kawai, Yuya,Kitagawa, Takuma,Masuda, Hideki,Matsunaga, Ayaka,Ozawa, Tomohiro,Wasada-Tsutsui, Yuko
-
supporting information
(2021/11/27)
-
- HETEROCYCLIC COMPOUNDS AND METHODS OF USE
-
The present invention discloses compounds useful in treatment of conditions associated with excessive activity of transforming growth factor beta (TGF-β), particularly type 1 or activin-like kinase 5 (ALK 5). Specifically the present invention discloses compound of formula (I) which exhibit inhibitory activity against ALK 5. Method of treating conditions associated with excessive activity (ALK 5) with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
- -
-
Paragraph 000215; 000217
(2020/02/06)
-
- MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS
-
The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
- -
-
Paragraph 0907
(2020/10/09)
-
- Optically Active Helical Lanthanide Complexes: Storable Chiral Lewis Acidic Catalysts for Enantioselective Diels–Alder Reaction of Siloxydienes
-
Lanthanide triflates and a series of hexadentate chiral ligand complexes were synthesized. X-ray-quality crystals were obtained from mixtures of the lanthanide complexes, which were helical in shape. The complexes showed Lewis acidity and catalyzed the enantioselective Diels–Alder reaction of electron-rich siloxydienes. The complexes were stable enough to be stored at ambient temperature on a laboratory bench and retained their Lewis acidity even after a month.
- Harada, Shinji,Nakashima, Saki,Nishida, Atsushi,Oishi, Wakana,Sekino, Shihori
-
supporting information
(2020/02/05)
-
- Photocatalytic CO2 Reduction by Trigonal-Bipyramidal Cobalt(II) Polypyridyl Complexes: The Nature of Cobalt(I) and Cobalt(0) Complexes upon Their Reactions with CO2, CO, or Proton
-
The cobalt complexes CoIIL1(PF6)2 (1; L1 = 2,6-bis[2-(2,2′-bipyridin-6′-yl)ethyl]pyridine) and CoIIL2(PF6)2 (2; L2 = 2,6-bis[2-(4-methoxy-2,2′-bipyridin-6′-yl)ethyl]pyridine) were synthesized and used for photocatalytic CO2 reduction in acetonitrile. X-ray structures of complexes 1 and 2 reveal distorted trigonal-bipyramidal geometries with all nitrogen atoms of the ligand coordinated to the Co(II) center, in contrast to the common six-coordinate cobalt complexes with pentadentate polypyridine ligands, where a monodentate solvent completes the coordination sphere. Under electrochemical conditions, the catalytic current for CO2 reduction was observed near the Co(I/0) redox couple for both complexes 1 and 2 at E1/2 = -1.77 and -1.85 V versus Ag/AgNO3 (or -1.86 and -1.94 V vs Fc+/0), respectively. Under photochemical conditions with 2 as the catalyst, [Ru(bpy)3]2+ as a photosensitizer, tri-p-tolylamine (TTA) as a reversible quencher, and triethylamine (TEA) as a sacrificial electron donor, CO and H2 were produced under visible-light irradiation, despite the endergonic reduction of Co(I) to Co(0) by the photogenerated [Ru(bpy)3]+. However, bulk electrolysis in a wet CH3CN solution resulted in the generation of formate as the major product, indicating the facile production of Co(0) and [Co-H]n+ (n = 1 and 0) under electrochemical conditions. The one-electron-reduced complex 2 reacts with CO to produce [Co0L2(CO)] with νCO = 1894 cm-1 together with [CoIIL2]2+ through a disproportionation reaction in acetonitrile, based on the spectroscopic and electrochemical data. Electrochemistry and time-resolved UV-vis spectroscopy indicate a slow CO binding rate with the [CoIL2]+ species, consistent with density functional theory calculations with CoL1 complexes, which predict a large structural change from trigonal-bipyramidal to distorted tetragonal geometry. The reduction of CO2 is much slower than the photochemical formation of [Ru(bpy)3]+ because of the large structural changes, spin flipping in the cobalt catalytic intermediates, and an uphill reaction for the reduction to Co(0) by the photoproduced [Ru(bpy)3]+.
- Shimoda, Tomoe,Morishima, Takeshi,Kodama, Koichi,Hirose, Takuji,Polyansky, Dmitry E.,Manbeck, Gerald F.,Muckerman, James T.,Fujita, Etsuko
-
supporting information
p. 5486 - 5498
(2018/05/17)
-
- Ruthenium PNN(O) Complexes: Cooperative Reactivity and Application as Catalysts for Acceptorless Dehydrogenative Coupling Reactions
-
The novel tridentate PNNOH pincer ligand LH features a reactive 2-hydroxypyridine functionality as well as a bipyridyl-methylphosphine skeleton for meridional coordination. This proton-responsive ligand coordinates in a straightforward manner to RuCl(CO)(H)(PPh3)3 to generate complex 1. The methoxy-protected analogue LMe was also coordinated to Ru(II) for comparison. Both species have been crystallographically characterized. Site-selective deprotonation of the 2-hydroxypyridine functionality to give 1′ was achieved using both mild (DBU) and strong bases (KOtBu and KHMDS), with no sign of involvement of the phosphinomethyl side arm that was previously established as the reactive fragment. Complex 1′ is catalytically active in the dehydrogenation of formic acid to generate CO-free hydrogen in three consecutive runs as well as for the dehydrogenative coupling of alcohols, giving high conversions to different esters and outperforming structurally related PNN ligands lacking the NOH fragment. DFT calculations suggest more favorable release of H2 through reversible reactivity of the hydroxypyridine functionality relative to the phosphinomethyl side arm.
- De Boer, Sandra Y.,Korstanje, Ties J.,La Rooij, Stefan R.,Kox, Rogier,Reek, Joost N. H.,Van Der Vlugt, Jarl Ivar
-
p. 1541 - 1549
(2017/04/28)
-
- Bipyridine ligand ruthenium complex is carried and its preparation method and application (by machine translation)
-
The invention relates to a novel bipyridine is carried ligand ruthenium complex and its preparation method and in the ester compound hydrogenation is the application of the alcohol compound in the reaction. The use of the bipyridine ligand ruthenium complex catalytic hydrogenation is carried ester compound alcohol compound method is characterized in that: in order to ester compound material in an amount of 0.001 - 0.3 μM % bipyridyl is carried ligand ruthenium complex as catalyst, adding esters compound material in an amount of 1 - 10mol % alkali, in the 25 - 100 °C and 1 - 10MPa hydrogen pressure catalytic hydrogenation under the conditions of ester compound corresponding alcohol compound. The invention of the bipyridine ligand ruthenium complex is carried is convenient to prepare, stable structure, in the ester compound in hydrogenation reaction exhibits excellent catalytic activity. This invention has overcome the ester compound or a non-homogeneous phase catalytic hydrogenation system requires high-temperature high-pressure reaction conditions and high defects of the catalyst amount, catalyst consumption is small, mild reaction conditions, the reaction selectivity is good, improves the economy and the safety of the production system. (by machine translation)
- -
-
Paragraph 0045; 0046
(2017/04/28)
-
- Ruthenium complexes of tetradentate bipyridine ligands: Highly efficient catalysts for the hydrogenation of carboxylic esters and lactones
-
A new type of readily available, air-stable ruthenium complex of tetradentate bipyridine ligands has been developed. These complexes displayed exceptional efficiency for the hydrogenation of aromatic and aliphatic carboxylic esters and lactones at as low as 10 ppm catalyst loading under very mild conditions. the Partner Organisations 2014.
- Li, Wei,Xie, Jian-Hua,Yuan, Ming-Lei,Zhou, Qi-Lin
-
supporting information
p. 4081 - 4085
(2014/10/15)
-
- Catalytic hydrosilylation of alkenes by iron complexes containing terpyridine derivatives as ancillary ligands
-
Iron complexes formulated as Fe(terpy)X2 (terpy = 2,2′:6′,2 -terpyridine derivatives; X = Cl, Br) were prepared and their catalytic activities for hydrosilylation of olefin with hydrosilane were examined. Although Fe(terpy)X2 did not
- Kamata, Kouji,Suzuki, Atsuko,Nakai, Yuta,Nakazawa, Hiroshi
-
p. 3825 - 3828
(2012/07/02)
-
- Unusual nitro-coordination of europium(iii) and terbium(iii) with pyridinyl ligands
-
A new ligand family based on picoline, bipyridine and terpyridine containing a nitro moiety has been synthesized and its coordination and sensitization ability for lanthanide ions has been studied. Three new complexes were characterized by X-ray single crystal diffraction and all three show uncommon coordination of the nitro moiety to the lanthanide ion. 5cTb, a terpyridine-nitro derivative with Tb(NO3)3, crystallizes in the orthorhombic space group Pbca with a = 15.125(3), b = 13.776(3), c = 18.716(4) A, and V = 3899.8(13) A3 and is isostructural with its Eu(iii) analog (5cEu) with cell parameters a = 15.1341(4), b = 13.7070(4), c = 18.8277(5) A. 6Eu, a tripodal amine with a nitro-derivatized pyridine with Eu(CF3SO3)3, crystallizes in the triclinic space group P1 with a = 11.067(2), b = 11.633(2), c = 12.772(3) A, α = 110.94(3), β = 97.49(3), γ = 91.42(3)° and V = 1518.1(5) A3. Finally, ligand 5a, a bipyridine-nitro derivative, crystallizes in the orthorhombic space group P21/n with a = 3.7128(3), b = 11.7806(8), c = 19.9856(14) A, β = 92.925(2)° and V = 873.01(11) A3. All four ligands show sensitization of Eu(iii) and Tb(iii) luminescence.
- De Bettencourt-Dias, Ana,Bauer, Sebastian,Viswanathan, Subha,Maull, Brandi C.,Ako, Ayuk M.
-
p. 11212 - 11218
(2012/10/29)
-
- LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS
-
The present invention relates to linear pyridazine compounds, and more particularly to those of these compounds which are oligopyridazine compounds, to processes for obtaining them, to their uses, and also to their reduction to pyrroles and to the uses of the pyrrole, pyridazinylpyrrole and oligopyrrole compounds obtained. The invention relates in particular to the uses as medicaments, in particular for treating pathologies such as cancer, bacterial infections or parasitic infections, and also the applications in the materials, environmental, electronics and optics field.
- -
-
Page/Page column 32
(2010/02/16)
-
- Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses
-
The present invention relates to nonlinear oligopyridazine compounds, to processes for obtaining them, to their uses, and also to their reduction to oligopyrroles and to the uses of the pyridazinylpyrrole and oligopyrrole compounds obtained. The invention relates in particular to the uses as medicaments, in particular for treating pathologies such as cancer, bacterial infections or parasitic infections, and also the uses in the materials, environmental, electronics and optics field.
- -
-
-
- PYRIDYL-AZA(THIO)XANTHONE SENSITIZER COMPRISING LANTHANIDE(III) ION COMPLEXING COMPOUNDS, THEIR LUMINESCENT LANTHANIDE (III) ION COMPLEXES AND USE THEREOF AS FLUORESCENT LABELS.
-
Lanthanide (III) Ion completing compound comprising: (1) a sensitizer moiety of Formula (I) in which: a is an integer from 1 to 4; b is an integer equal to 1 or 2; c is an integer equal to 1 or 2; (R1)a, (R2)b, (R3)C are t
- -
-
Page/Page column 36; 37
(2010/08/08)
-
- MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
-
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
- -
-
Page/Page column 103-104
(2008/06/13)
-
- HIV protease inhibiting compounds
-
A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
- -
-
Page/Page column 127
(2010/02/12)
-
- DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES
-
The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumor diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.
- -
-
Page/Page column 105
(2008/06/13)
-
- Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
-
This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
- -
-
-
- NOVEL SULFONYL DERIVATIVES
-
Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.
- -
-
-
